Business Wire

Mars Petcare Marks Strategic Entry into European Veterinary Care Sector as Anicura to Join the Business

Jaa

Mars Petcare today announced that it has signed definitive agreements to acquire AniCura from Nordic Capital, Fidelio Capital and the remaining minority shareholders of AniCura. On completion of the transaction, AniCura will join the family of Mars Petcare’s veterinary health business units and will continue to pursue the expansion of its brand and high quality standards of medicine in Europe.

AniCura was founded in 2011 as the first merger of animal hospitals in the Nordic region. Since then, it has grown to become a role model for high-quality, specialized veterinary care for companion animals. AniCura now has more than 4,000 veterinary professionals, and 200 animal hospitals in seven countries across Europe. Its vision is to provide a first-class customer experience for pet owners and referring veterinarians alike.

The acquisition of AniCura represents Mars Petcare’s strategic entry into the European veterinary care sector. It brings together Mars Petcare’s notable veterinary expertise with AniCura’s well-established European business. This follows the announcement earlier in June 2018 that Linnaeus – a high-quality provider of veterinary care based in the UK – will also join Mars Petcare and will become a unit within Mars Petcare’s Veterinary Health Group.

Mars Petcare has been providing veterinary care since 1994 when it first began partnering with BANFIELD™ Pet Hospital. Today, it employs approximately 50,000 veterinary professionals and cares for more than 10 million pets annually. AniCura will join the family of Mars Petcare’s veterinary businesses alongside VCA™, BANFIELD™ Pet Hospital, BLUEPEARL™, PET PARTNERS™ and Linnaeus. Mars Petcare’s purpose is to create A BETTER WORLD FOR PETS and it is building upon and leveraging capabilities across its pet businesses to bring this to life. This includes food & nutrition, research, technology, and veterinary expertise – from wellness and prevention, through all aspects of veterinary care.

“Mars Petcare has a long and global history of providing nutrition, veterinary care and science for pets across the globe. Our veterinary business until now has been in the United States and Canada. Europe is the second largest region in the world for pet care, and European pet care is expected to grow significantly over the coming years. There is a great opportunity to address growing demand by providing high quality, consistent veterinary care across Europe”, said Poul Weihrauch, President, Mars Petcare. “Together, Mars Petcare and AniCura will both be in a position to benefit from each other’s best practices and competencies, improving clinical practice and continuing to advance the veterinary profession in both North America and Europe. This will support us in our purpose to create A BETTER WORLD FOR PETS.”

AniCura is well renowned for practicing quality medicine across its 200 animal hospitals and for the two million pets it cares for every year. It has well-regarded specialist care focus and a highly-qualified team, employing a high share of Diplomates from the European College across Sweden, Norway, Denmark, Germany, Austria, Switzerland and The Netherlands.

“Over the past years, with support from Nordic Capital and the additional owners, AniCura has grown to become a leading European provider of high-quality veterinary care, well-known for its focus on people, customer care and quality. The company is now ready to take the next step in its development”, said Peter Dahlberg, Chief Executive Officer, AniCura. “It was clear from early on that Mars Petcare shared our values of providing high-quality veterinary care and a first-class customer experience, and we are pleased to have found a long-term owner for AniCura to further improve the quality of European veterinary care”.

Completion of the transaction is subject to customary regulatory approvals. It is expected that the transaction will close in Q4 2018.

On completion of the deal, AniCura’s existing management will continue to lead the business. As part of the Mars Petcare family, AniCura will continue with the expansion of its brand and high quality standards of medicine in Europe. Financial terms of the transaction were not disclosed.

J.P. Morgan Securities plc acted as financial adviser and Freshfields Bruckhaus Deringer LLP and Cederquist acted as legal counsel to Mars.

About Mars Petcare

Mars Petcare is a diverse and growing business with 75,000 Associates across 50+ countries dedicated to one purpose: A BETTER WORLD FOR PETS. With 75 years of experience, our portfolio of almost 50 brands serves the health and nutrition needs of the world’s pets – including brands PEDIGREE ®, WHISKAS ®, ROYAL CANIN®, NUTRO™, GREENIES™, SHEBA ®, CESAR ®, IAMS™ and EUKANUBA™ as well as The WALTHAM Centre for Pet Nutrition which has advanced research in the nutrition and health of pets for over 50 years. Mars Petcare is also a leading veterinary health provider through a network of over 2,000 pet hospitals including BANFIELD™, BLUEPEARL™, PET PARTNERS™, and VCA™. We’re also active in innovation and technology for pets, with WISDOM PANEL™ genetic health screening and DNA testing for dogs, the WHISTLE™ GPS dog tracker, and LEAP VENTURE STUDIO accelerator and COMPANION FUND™ programs that drive innovation and disruption in the pet care industry. As a family business and guided by our principles, we are privileged with the flexibility to fight for what we believe in – and we choose to fight for: A BETTER WORLD FOR PETS.

About AniCura

AniCura is a family of well-known animal hospitals and clinics specialised in veterinary care for companion animals. Born out of the idea that sharing resources creates opportunities for better veterinary care, the company was established in 2011 by Fidelio Capital and The Animal Foundation in Greater Stockholm as the first merger of companion animal hospitals in the Nordic region. Today, AniCura is a role model within specialised veterinary care and a valued partner for pet owners and referring veterinarians across Europe. AniCura offers a wide range of high quality medical services covering preventive and basic health care as well as advanced diagnostics, internal medicine, intensive care, surgery and orthopaedics. AniCura also provides rehabilitation, physiotherapy and dietary advice and offers selected pet food and care products. AniCura provides modern, high-quality veterinary care for pets at 200 European locations and creates peace of mind for pet owners through excellent access and patient safety. Every year, AniCura’s 4,000 passionate veterinary professionals attend to more than two million companion animal patients. AniCura is a trusted training and referral body. For information on how AniCura is working to shape the future of veterinary care, please visit our website www.anicuragroup.com.

About Nordic Capital

Nordic Capital is a leading private equity investor in the Nordic region with a resolute commitment to creating stronger, sustainable businesses through operational improvement and transformative growth. Nordic Capital focuses on selected regions and sectors where it has deep experience and a proven track record. Core sectors are Healthcare, Technology & Payments, Financial Services, Industrial Goods & Services and Consumer & Retail, and key regions are the Nordics, Northern Europe, and globally for Healthcare. Since inception in 1989, Nordic Capital has invested EUR 12 billion in 100 investments. The Nordic Capital Funds are based in Jersey and are advised by advisory entities, which are based in Sweden, Denmark, Finland, Norway, Germany and the UK. For further information about Nordic Capital, please visit www.nordiccapital.com.

###

Contact information

CNC for Mars Petcare
Maximilian Karpf
maximilian.karpf@cnc-communications.com
or
Matthew Thomlinson
matthew.thomlinson@cnc-communications.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

REPLY Study on Artificial Intelligence: Quo vadis, AI?23.1.2019 13:00Tiedote

Artificial intelligence enable machines to better understand the surrounding context, giving them the ability to recognise sight, sound and speech. This is made possible by machine learning algorithms. A current study by Reply, conducted with the trend platform SONAR, shows which trends are still relevant in this area. The study highlights some aspects of the future potential of Artificial Intelligence (AI). Complex algorithms, Edge Computing tools that reduce latency periods and AI-specific hardware are yielding many new products and services for mobile computing, the Internet of Things (IoT) and Human-machine Interfaces. There are many different possible scenarios, and three trends play a major role in determining AI’s future as a game changer: AI-driven analytics In the era of digital transformation, decisions are made based on data with the help of predictive analytics. Companies in diverse industries use AI-as-a-service solutions from established providers or start-ups and increas

GSMA Announces Nominees for 2019 GLOMO Awards23.1.2019 12:00Tiedote

The GSMA today announced the nominees for the Global Mobile Awards 2019 (GLOMO Awards). Winners of the awards will be presented throughout MWC19 Barcelona, which takes place 25 - 28 February. The full list of nominees can be found at www.mwcbarcelona.com/conference-programmes/global-mobile-awards/global-mobile-awards-2019-nominee-shortlist/. “The GLOMOs provide a world stage on which to celebrate the most inspirational and innovative developments across our industry, recognising the companies and individuals leading the way in everything from 5G, to emerging markets, to intelligent connectivity,” said John Hoffman, CEO, GSMA Ltd. “The awards attract a significant level of high-quality entries, so being nominated today is a great achievement. We wish everyone the very best of luck and we look forward to some exciting announcements at MWC19 Barcelona.” The GLOMO Awards feature an afternoon ceremony at 16:30 CET on Tuesday, 26 February in Auditorium 5, Hall 4, and will include the present

Y Analytics Launches to Bring Together Capital and Research for Good23.1.2019 11:58Tiedote

Today marks the launch of Y Analytics, a new, independent organization established to drive increased and more effective investment in creating social and environmental good by equipping capital allocators with the research basis to effectively understand the impact of their decisions. The organization, headquartered in Washington, D.C. and led by Maryanne Hancock, will help bridge the divide between the research community and capital allocators. Ultimately, this will ensure that capital directed at addressing the United Nations Sustainable Development Goals is used most efficiently, and more broadly, that we advance our abilities to direct capitalism towards solutions that have the potential to create real, tangible impact. From Maryanne Hancock, CEO of Y Analytics: “We are building on the extensive effort of others, who have worked for decades to advance the world’s understanding of what creates impact. Y Analytics is built on the premise of learning from their work, utilizing resear

SpeeDx Increase European Distribution Network23.1.2019 11:00Tiedote

SpeeDx have announced signing two new distribution partners, creating comprehensive access for customers to market-leading SpeeDx ResistancePlus ® and PlexPCR ® tests across Europe. AB ANALITICA will distribute throughout Italy and Immuno Diagnostic Oy will cover Finland. “Our new distribution partners have strong sales presence in their regions and close working relationships with the key customers that are interested in our solutions,” says Colin Denver, SpeeDx CEO. “Antibiotic resistance in sexually transmitted diseases is a top concern for authorities and testing bodies across Europe, and now more laboratories can access our ResistancePlus tests for Mycoplasma genitalium and gonorrhoea to help address the real need for Resistance Guided Therapy.” The SpeeDx ResistancePlus portfolio includes ResistancePlus GC* (CE-IVD) - the first commercially available test that combines Neisseria gonorrhoeae (GC) detection with markers for ciprofloxacin susceptibility. ResistancePlus GC enables st

Nikon, ASML And Carl Zeiss Sign Agreement to Settle All Litigation23.1.2019 10:02Tiedote

Nikon Corporation (“Nikon”) (TYO: 7731), ASML Holding N.V. (“ASML”) (NASDAQ: ASML) and Carl Zeiss SMT GmbH (“Zeiss”) have signed a Memorandum of Understanding relating to a comprehensive settlement of all legal proceedings over patents for lithography equipment and digital cameras. The Memorandum of Understanding is a binding agreement that concerns all pending disputes between Nikon, ASML and Zeiss in Europe, Japan and the United States, including at the U. S. International Trade Commission. The three companies expect to execute a definitive settlement and cross-license agreement and dismiss all legal proceedings between the parties in February 2019. The terms of the Memorandum include a payment to Nikon by ASML and Zeiss of a total of EUR 150 million (approximately 19.0 billion Japanese Yen*). Furthermore, the cross-license agreement contemplated by the Memorandum includes mutual royalty payments of 0.8% over the sales of immersion lithography systems for 10 years from the signature

PMI Explores Global Public Health Issues in New White Paper23.1.2019 10:00Tiedote

In a new White Paper, “Public Health—Much Harder than Rocket Science,” Philip Morris International (PMI) (NYSE:PM) looks at the dynamics between consumers, corporations and authorities across a range of global public health issues. It is based on a recent global survey conducted by IPSOS. Consumers all over the world want their governments to do better at solving major public health issues, according to the IPSOS survey of 31,000 respondents across 31 countries commissioned by PMI. In the survey, respondents were asked how important they believed it is for governments to dedicate time and resources to nine global health issues: air pollution, mental health, STDs, healthier food products, opioid abuse, smoking and alcohol abuse, unwanted pregnancies and obesity. When asked about the role of technology and innovation in addressing these issues, 91 per cent of respondents believed technology and innovation had an important role to play. However, respondents did not evaluate government per

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme